-$0.40 Earnings Per Share Expected for Profound Medical Corp. (NASDAQ:PROF) This Quarter

Equities research analysts forecast that Profound Medical Corp. (NASDAQ:PROF – Get Rating) will report earnings of ($0.40) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Profound Medical’s earnings. The highest EPS estimate is ($0.39) and the lowest is ($0.41). Profound Medical posted earnings of ($0.35) per share during the same quarter last year, which would suggest a negative year over year growth rate of 14.3%. The firm is expected to announce its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Profound Medical will report full-year earnings of ($1.31) per share for the current year, with EPS estimates ranging from ($1.60) to ($0.94). For the next financial year, analysts anticipate that the company will post earnings of ($1.00) per share, with EPS estimates ranging from ($1.49) to ($0.46). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Profound Medical.

Profound Medical (NASDAQ:PROF – Get Rating) last issued its quarterly earnings data on Thursday, March 3rd. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.14). The company had revenue of $1.00 million during the quarter, compared to analyst estimates of $2.80 million. Profound Medical had a negative net margin of 417.41% and a negative return on equity of 37.74%. During the same period last year, the firm earned ($0.38) EPS.

PROF has been the subject of a number of analyst reports. Cowen reduced their price target on Profound Medical from $28.00 to $14.00 and set an “outperform” rating for the company in a report on Monday, March 7th. Alliance Global Partners reduced their price target on Profound Medical from $16.25 to $12.00 and set a “buy” rating for the company in a report on Tuesday, May 10th. Raymond James set a $22.00 price objective on Profound Medical and gave the stock an “outperform” rating in a research note on Tuesday, May 10th. Finally, Zacks Investment Research upgraded Profound Medical from a “sell” rating to a “hold” rating in a research note on Friday, May 13th.

NASDAQ PROF traded up $0.47 during trading hours on Tuesday, reaching $7.07. The company’s stock had a trading volume of 97,587 shares, compared to its average volume of 54,610. The firm has a market capitalization of $146.91 million, a price-to-earnings ratio of -4.62 and a beta of 1.11. Profound Medical has a 1-year low of $6.09 and a 1-year high of $19.32. The company’s 50-day moving average is $8.16 and its two-hundred day moving average is $9.65.

A number of institutional investors have recently modified their holdings of PROF. CVI Holdings LLC acquired a new position in Profound Medical during the third quarter worth $146,000. D. E. Shaw & Co. Inc. acquired a new position in Profound Medical during the fourth quarter worth $121,000. Harbor Advisors LLC acquired a new position in Profound Medical during the fourth quarter worth $139,000. Jane Street Group LLC acquired a new position in Profound Medical during the first quarter worth $132,000. Finally, Wealth Management Partners LLC acquired a new position in Profound Medical during the first quarter worth $230,000. Institutional investors own 60.23% of the company’s stock.

About Profound Medical (Get Rating)

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland.

Featured Articles